Skip to main content

Table 6 Patients’ characteristics

From: Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis

eGFRAge (years)SUA (mmol/L)25-OH-VitD (ng/mL)Glycemia (mmol/L)HbA1c (%)Triglycerides (mmol/L)Total cholesterol (mmol/L)LDL (mmol/L)
< 90 mL/min/1.73 m241.64 ± 10.390.38 ± 0.1026.85 ± 13.235.29 ± 1.315.98 ± 1.021.31 ± 0.644.50 ± 1.052.21 ± 0.92
90–119 mL/min/1.73 m234.63 ± 10.800.34 ± 0.0825.55 ± 9.705.41 ± 2.095.69 ± 0.931.07 ± 0.603.90 ± 1.021.97 ± 0.79
≥ 120 mL/min/1.73 m228.54 ± 10.520.32 ± 0.0921.96 ± 7.805.29 ± 1.315.98 ± 1.020.89 ± 0.393.41 ± 1.131.72 ± 0.89
p value (using ANOVA)0.0010.0050.1970.6710.1460.0050.0010.040
  1. Lipid and Metabolic profile in relation to eGFR and age in CF patients. Data are shown as Average ± SD
  2. CF cystic fibrosis, eGFR estimated Glomerular Filtration Rate, LDL low-density, SUA Serum Uric Acid, 25-OH-VitD 25-hydroxy-vitamin D, HbA1c hemoglobin A1c. lipoprotein cholesterol, CF cystic fibrosis